Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
Clinical trial NCT05020873 · TERMINATED
Trial details
- NCT number
- NCT05020873
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Study type
- OBSERVATIONAL
- Start date
- 2021-11-04
- Primary completion
- 2023-08-31
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.